Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Should Pregnant Women Be Included In National Childrens' Study?
An ambitious new national study that aims to follow children from conception through adulthood will miss a golden opportunity to gather data on the most underrepresented population in clinical research - pregnant women, say leading ethicists at Duke University Medical Center, Johns Hopkins and Georgetown Universities.
generic viagra online
Autism Spectrum Therapies Offers New Summer Programs & Services For Children With Autism And Their Families In Southern California
Autism Spectrum Therapies (AST), an agency providing behavior therapy and other autism services, now offers new summer programs for children of all ages and their parents. These fun, kid-friendly programs are designed to help children with autism disorders maintain their academic and communication skills over summer vacation and to develop new skills for the upcoming school year.
News of the day
Synosia Therapeutics Begins Phase I Trial Of A New Generation Treatment For Cognitive Impairment In Alzheimer's Disease And Schizophrenia
Synosia Therapeutics announced today that it has started a Phase I clinical trial of SYN-120, its new generation 5-HT6 antagonist under development for the treatment of cognitive impairment associated with Alzheimer"s and schizophrenia. The study will assess the safety and tolerability of single ascending doses of SYN-120 in healthy volunteers.
Mental Health

InDex Pharmaceuticals AB Engages PharmaVentures To Facilitate The Licensing Of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early

PharmaVentures Ltd, announced that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD). The engagement will utilise PharmaVentures" transactions experience in the healthcare and investment business sectors. Kappaproct, approved for Orphan Drug Designation in Europe, has recently successfully concluded its third clinical phase II trial for the treatment of Inflammatory Bowel Disease patients. Due to the highly positive interim results at both one and four weeks after dosing, this trial, which included 34 patients and was conducted as a multi-center study in Sweden and Russia, was concluded early. Kappaproct showed the same excellent safety profile as seen in previous trials. Kappaproct is currently approved for clinical developmental use as a rectal, single-dose administration. Qualification of the compound for other routes of administration and multiple dosing is underway through an extended toxicology program. Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures is very pleased to be involved in bringing this groundbreaking technology to the market. InDex are leaders in the field of immunomodulation via Toll Like Receptors." A leading results driven organisation, PharmaVentures assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company"s core business is the provision of tailored consulting and transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals range of intelligence products which include analysis tools and reports. InDex Pharmaceuticals AB ("InDex") is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its DIMS platform (DNA-based immunomodulatory sequence). DIMS drugs are developed to treat diseases within a variety of therapeutic areas, including inflammation and cancer. InDex has several proprietary DIMS compounds in various stages of development, including Kappaproct, for the treatment of steroid resistant/dependent ulcerative colitis. PharmaVentures


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009